Browse
Submit Data
Databases
API
Help

Dataset Information

17 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A Phase I /II Study of Bi-weekly XELIRI with Bevacizumab for patient with Metastatic Colorectal Cancer as second-line chemotherapy.

ABSTRACT: Interventions: XELIRI+ bevacizumab Capecitabine:2000mg/m2/day d1-8 Irinotecan:180mg/m2 d1 Bevacizumab:5mg/kg d1 Q2w Primary outcome(s): Phase I part To determine Safety in 1st cycle by Bi-weekly XELIRI+bevacizumab. Phase II part Progression Free Survival Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2619445 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

A phase II study of Perioperative FOLFOX4 plus Bevacizumab for initially unresectable Advanced Colorectal Cancer.

Project description:Interventions: FOLFOX4+Bevacizumab 5FU bolus: 400 mg/m2 d1,2 5FU infusion: 600 mg/m2/22h d1,2 Oxaliplatin: 85mg/m2 d1 l-LV: 100mg/m2 d1,2 bevacizumab: 5mg/kg d1 Bevacizumab 5mg/m2 d1 Q2w Primary outcome(s): Completion rate of neoadjuvant chemotherapy. Possibility of curative surgery. Study Design: Single arm Non-randomized

| 2621009 | ecrin-mdr-crc

Prospective cohort study of optimal discontinuation of oxaliplatin in elderly patients treated with XELOX plus bevacizumab

Project description:Interventions: XELOX+BEV Capecitabine:2000mg/m2 d1-14 Oxaliplatin:130mg/m2 d1 Bevacizumab:7.5mg/kg d1 Q3w Discontinuation of oxaliplatin when neurotoxicity develops >=Grade2 Primary outcome(s): Rate of Grade3 neuropathy Study Design: Single arm Non-randomized

| 2631347 | ecrin-mdr-crc

A Phase I /II Study of Tri-weekly XELIRI with Bevacizumab for patient with Metastatic Colorectal Cancer as second-line chemotherapy.

Project description:Interventions: XELIRI+ bevacizumab Primary outcome(s): Phase I part Estimated the dose limiting toxicities in 1st cycle. Phase II part Progressiom Free Survival Study Design: Single arm Non-randomized

| 2618941 | ecrin-mdr-crc

A Phase II Study of Bi-weekly XELIRI with Bevacizumab for patient with Metastatic Colorectal Cancer as second-line chemotherapy

Project description:Interventions: XELIRI plus bevacizumab therapy Capecitabine: 2000 mg/m2 day1 to 8 CPT11 150mg/m2 day1 Bevacizumab: 10mg/kg day 1 The treatment is repeated every two weeks until disease progression or severe toxicity. Primary outcome(s): progression free survival and safety Study Design: Single arm Non-randomized

| 2624679 | ecrin-mdr-crc

Single-arm phase II exploratory study of cetuximab combined with camrelizumab in RAS wild-type recurrent or distantly metastatic advanced colorectal cancer after failure of second-line standard therapy

Project description:Interventions: Experimental group:Cetuximab:500mg/m2,d1,q2w Camrelizumab:200mg, d1, q2w Primary outcome(s): Objective response rate Study Design: Single arm

| 85219 | ecrin-mdr-crc

A phase II study of Oxaliplatin Reintroduction in patients pretreated with Oxaliplatin and Irinotecan for Advanced Colorectal Cancer

Project description:Interventions: mFOLFOX6 5FU bolus: 400 mg/m2 d1 5FU infusion: 2400 mg/m2/46h d1 Oxaliplatin: 85mg/m2 d1 l-LV: 200mg/m2 d1 Q2w Primary outcome(s): Disease control rate after 12 weeks of treatment. Study Design: Single arm Non-randomized

| 2620327 | ecrin-mdr-crc

A feasibility study of capecitabine and oxaliplatin (XELOX) for patients with stage II/III colon cancer.

Project description:Interventions: XELOX Capecitabine:2000mg/m2 d1-14 Oxaliplatin:130mg/m2 d1 Q3w Primary outcome(s): Completion rate of treatment Study Design: Single arm Non-randomized

| 2623439 | ecrin-mdr-crc

Phase II study of XELIRI and bevacizumab as second-line therapy in patients with metastatic colorectal cancer

Project description:Interventions: XELIRI plus bevacizumab therapy Bevacizumab 7.5mg/kg day1 Irinotecan 160mg/m2 day1 Capecitabin 1,600mg/m2/day day1-15 Primary outcome(s): Progression Free Survival Study Design: Single arm Non-randomized

| 2624073 | ecrin-mdr-crc

Phase II study of XELIRI and High-dose bevacizumab as second-line therapy in patients with metastatic colorectal cancer

Project description:Interventions: XELIRI plus bevacizumab therapy Bevacizumab 10mg/kg day1 Irinotecan 150mg/m2 day1 Capecitabin 2,000mg/m2/day day1-8 Primary outcome(s): Progression Free Survival Study Design: Single arm Non-randomized

| 2623833 | ecrin-mdr-crc

Multicenter randomized phase ll study of XELOX plus bevacizumab or XELIRI plusbevacizumab as first-line chemotherapy for metastatic or recurrent colorectal cancer

Project description:Interventions: XELOX plus bevacizumab therapy Bevacizumab 7.5mg/kg day1 Oxaliplatin 130mg/m2 day1 Capecitabin 2,000mg/m2/day day1-15 XELIRI plus bevacizumab therapy Bevacizumab 7.5mg/kg day1 Irinotecan 200mg/m2 day1 Capecitabin 1,600mg/m2/day day1-15 Primary outcome(s): ORR; Overall response rate Study Design: Parallel Randomized

| 2622964 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data